2.3.5-trimethyl-6-(3-hydroxy-3-methyl-butyl)-hydroquinone | 67120-56-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2.3.5-trimethyl-6-(3-hydroxy-3-methyl-butyl)-hydroquinone
• 英文别名: 3.6-Dihydroxy-1.2.4-trimethyl-5-(3-hydroxy-3-methyl-butyl)-benzol；2.3.5-Trimethyl-6-(3-hydroxy-3-methyl-butyl)-hydrochinon；2-(3-Hydroxy-3-methylbutyl)-3,5,6-trimethylbenzene-1,4-diol
• CAS: 67120-56-3
• 化学式: C₁₄H₂₂O₃
• 分子量: 238.327
• InChiKey: MULBYLCZJVZSIX-UHFFFAOYSA-N

物化性质

• 熔点：
  154.5-156 °C
• 沸点：
  414.9±40.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2.3.5-trimethyl-6-(3-hydroxy-3-methyl-butyl)-hydroquinone 在 硫酸 作用下， 生成 3,4-二氢-2,2,5,7,8-五甲基-2H-1-苯并吡喃-6-酚
  参考文献：
  名称：

  Effects of phosphate fertilizer levels on cowpea pod-sucking bug populations and damage

  摘要：

  The effect of different application levels of phosphate fertilizer on cowpea pod-sucking bugs [Clavigralla sp., Riptortus sp., Anoplocnemis., Mirperus sp. and Negara sp. (Heteroptera)] was studied using 0 (control), 20, 40 and 60 kg/ha of single super-phosphate. The results showed that the bug densities decreased significantly with increase in rate of application. At 40 and 60 kg/ha, grain yields were significantly higher than at the lower rates of application. Crude protein, fibre, oxalate, phytin, potassium and magnesium contents as well as seed hardness also increased with increase in the rate of fertilizer application.

  DOI：

  10.1080/096708700415544
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 溶剂黄146 、 锌 作用下， 生成 2.3.5-trimethyl-6-(3-hydroxy-3-methyl-butyl)-hydroquinone
  参考文献：
  名称：

  Effects of phosphate fertilizer levels on cowpea pod-sucking bug populations and damage

  摘要：

  The effect of different application levels of phosphate fertilizer on cowpea pod-sucking bugs [Clavigralla sp., Riptortus sp., Anoplocnemis., Mirperus sp. and Negara sp. (Heteroptera)] was studied using 0 (control), 20, 40 and 60 kg/ha of single super-phosphate. The results showed that the bug densities decreased significantly with increase in rate of application. At 40 and 60 kg/ha, grain yields were significantly higher than at the lower rates of application. Crude protein, fibre, oxalate, phytin, potassium and magnesium contents as well as seed hardness also increased with increase in the rate of fertilizer application.

  DOI：

  10.1080/096708700415544

文献信息

• Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
  申请人：Miller M. Guy

  公开号：US20070225261A1

  公开（公告）日：2007-09-27

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明揭示了治疗或抑制线粒体疾病的方法，例如弗里德雷希共济失调症（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或克恩斯-萨耶综合征（KSS），以及在该方法中有用的化合物。还揭示了用于治疗其他疾病的方法和化合物。还揭示了有用于评估受试者代谢状态和治疗效果的能量生物标志物。还揭示了调节、规范或增强能量生物标志物的方法，以及用于此类方法的化合物。
• SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
  申请人：Edison Pharmaceuticals, Inc.

  公开号：US20160244392A1

  公开（公告）日：2016-08-25

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明揭示了用于治疗或抑制线粒体疾病的方法，例如弗里德莱希共济失调症（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或科恩斯-萨耶综合症（KSS），以及在该方法中有用的化合物。本发明还揭示了用于治疗其他疾病的方法和化合物。本发明还揭示了用于评估受试者代谢状态和治疗效果的能量生物标志物。本发明还揭示了调节、规范或增强能量生物标志物的方法，以及用于该方法的化合物。
• Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers
  申请人：Edison Pharmaceuticals, Inc.

  公开号：EP2332534A1

  公开（公告）日：2011-06-15

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明公开了治疗或抑制线粒体疾病的方法，如弗里德雷希共济失调（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或卡恩斯-赛尔综合征（KSS），以及用于本发明方法的化合物。本发明还公开了用于治疗其他疾病的方法和化合物。还公开了用于评估受试者代谢状态和治疗效果的能量生物标记物。本发明还公开了调节、正常化或增强能量生物标志物的方法以及用于此类方法的化合物。
• Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
  申请人：Edison Pharmaceuticals, Inc.

  公开号：EP2617418A1

  公开（公告）日：2013-07-24

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Keams-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明公开了治疗或抑制线粒体疾病的方法，如弗里德雷希共济失调（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或基姆斯-赛尔综合征（KSS），以及用于本发明方法的化合物。本发明还公开了用于治疗其他疾病的方法和化合物。还公开了用于评估受试者代谢状态和治疗效果的能量生物标志物。本发明还公开了调节、正常化或增强能量生物标志物的方法以及用于此类方法的化合物。
• PHENOL AND 1,4-BENZOQUINONE DERIVATIVES FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES
  申请人：BioElectron Technology Corporation

  公开号：EP2617418B1

  公开（公告）日：2017-11-22